Stock Ratings / Health Care / IAM / financials

SLDB (31) CADL (38) ATTO (47) SLBT (47) ⌘ Pro Terminal →

Iambic Therapeutics Inc. (IAM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$14.28 -3.38% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Iambic Therapeutics Inc. (IAM) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $676.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IAM)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How IAM Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$19.0M (0.5% FCF Margin)

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IAM)

✓Walkthrough of IAM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IAM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -24.48%

2026-10-30O $13.10H $14.28L $12.39C $14.28VOL 476.7K

SMA50: $15.96

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IAM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IAM Butterfly Map → + Track IAM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IAM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IAM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IAM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IAM)

Health Care Rank #343 of 1016 ⚔️ SLDB vs IAM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IAM vs. SLDB, CADL, ATTO, SLBT)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Iambic Therapeutics Inc. (IAM) ranks #343 by composite RQD confidence (50/100, grade D) and #404 by equity capitalization ($676.9M). Within this direct 5-issuer industry benchmark cohort, IAM leads on earnings valuation at N/A trailing P/E, while SLDB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IAM currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IAM ACTIVE Iambic Therapeutics Inc.	D	50/100	—	—	—	-3.38%	$676.9M	Benchmark Subject
SLDB Solid Biosciences Inc.	E	31/100	—	—	-35.0%	-1.39%	$685.2M	/sldb-vs-iam →
CADL Candel Therapeutics Inc.	D-	38/100	—	—	-35.0%	-0.23%	$661.9M	/cadl-vs-iam →
ATTO Attovia Therapeutics Inc.	D	47/100	—	—	—	-3.35%	$697.1M	/atto-vs-iam →
SLBT SL Science Holding Limited	D	47/100	—	—	—	-3.31%	$656.1M	/slbt-vs-iam →

2. IAM Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Iambic Therapeutics Inc. (IAM) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $676.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. IAM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IAM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Iambic Therapeutics Inc. (NASDAQ: IAM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $14.28 (-3.38% 1D, market cap $676.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IAM ranks #343 in composite RQD confidence.

How does IAM compare to SLDB and CADL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IAM carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SLDB (Solid Biosciences Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $685.2M) and CADL (Candel Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $661.9M). Among the 5-stock peer group, IAM leads on earnings multiple (N/A) while SLDB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IAM?

For Iambic Therapeutics Inc. (IAM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #343 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IAM trading relative to its 50-day, 200-day, and 52-week technical levels?

IAM last traded at $14.28 (-3.38% on volume of 270,840 shares), positioning the stock -2.66% below its 50-day simple moving average ($14.67) and -2.59% below its 200-day simple moving average ($14.66). Across its 52-week range of $12.39 to $25.00, IAM sits at the 15.0% percentile with a 14-day RSI of 38.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($12.50 to $16.06).